Moderna COVID-19 Vaccine Dosage

Generic name: CX-038839 OMICRON (XBB.1.5) 25ug in 0.25mL
Dosage form: injection, suspension
Drug class: Viral vaccines

Medically reviewed by Drugs.com. Last updated on Mar 31, 2025.

For intramuscular use.

2.1 Preparation for Administration

•: If pre-filled syringes of Moderna COVID-19 Vaccine are frozen, thaw before use following the instructions below.

	Thaw in Refrigerator 2°C to 8°C (36°F to 46°F)	Thaw at Room Temperature 15°C to 25°C (59°F to 77°F)
Carton of 10 syringes	Thaw for 2 hours and 40 minutes	Thaw for 1 hour and 20 minutes
Carton of 2 syringes	Thaw for 1 hour and 40 minutes	Thaw for 40 minutes
One syringe (removed from carton)	Thaw for 1 hour and 40 minutes	Thaw for 40 minutes

•

After thawing, do not refreeze.

•

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

•

Moderna COVID-19 Vaccine is a white to off-white suspension. It may contain white or translucent product-related particulates. Do not administer if vaccine is discolored or contains other particulate matter.

•

Do not shake. Discard after single use.

o: With tip cap upright, remove tip cap by twisting counterclockwise until tip cap releases. Remove tip cap in a slow, steady motion. Avoid pulling tip cap while twisting.
o: Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe.

Administration

Administer the 0.25 mL dose of Moderna COVID-19 Vaccine intramuscularly.

Dose and Schedule

Individuals 6 Months Through 4 Years of Age by Moderna COVID-19 Vaccination Status

Number of Previous Doses of Moderna COVID-19 Vaccine(s)a	Moderna COVID-19 Vaccine (2024-2025 Formula) Dosing Regimen, Dose and Scheduleb
a Previous dose refers to a dose of any prior Moderna COVID-19 Vaccine that is no longer authorized for use in the United States. b For individuals with certain kinds of immunocompromise previously vaccinated with a Moderna COVID-19 vaccine, see text following the tables for dosing information. c Not previously vaccinated with any COVID-19 vaccine. d Individuals turning from 4 years to 5 years of age during the vaccination series should receive both doses with Moderna COVID-19 Vaccine (2024-2025 Formula).
0c	2 doses,d 0.25 mL each Dose 1: month 0 Dose 2: month 1
1	Single Dose, 0.25 mL One month after receipt of a previous dose of Moderna COVID-19 vaccinea
≥2	Single dose, 0.25 mL ≥2 months after receipt of the last previous dose of Moderna COVID-19 vaccinea

Individuals 5 Years Through 11 Years of Age Irrespective of COVID-19 Vaccination Status

a For individuals with certain kinds of immunocompromise, see text following tables for dosing information.
b Previous dose refers to a dose of any prior COVID-19 vaccine that is no longer authorized for use in the United States.

Moderna COVID-19 Vaccine (2024-2025 Formula)

Dosing Regimen, Dose and Schedulea

Single dose, 0.25 mL

(If previously vaccinated, administer the dose ≥2 months after receipt of the last previous dose of COVID-19 vaccineb)

Individuals 6 Months through 11 Years of Age with Certain Kinds of Immunocompromise

Individuals 6 months through 11 years of age with certain kinds of immunocompromise1 should complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart.2 At least 1 dose should be with a COVID-19 vaccine (2024-2025 Formula).

•: If previously not vaccinated, complete the three-dose series with Moderna COVID-19 Vaccine (2024-2025 Formula).
•: If previously vaccinated with one or two dose(s) of any prior formula of Moderna COVID-19 Vaccine,3 complete the remaining dose(s) in the three-dose series with Moderna COVID-19 Vaccine (2024-2025 Formula).
•: If previously vaccinated with three or more doses of any prior formula of COVID-19 vaccines,5 administer a single dose of Moderna COVID-19 Vaccine (2024-2025 Formula) at least two months following the last dose.

An additional dose of Moderna COVID-19 Vaccine (2024-2025 Formula) may be administered at least 2 months following the last dose of a COVID-19 vaccine (2024-2025 Formula).4,5 Additional doses of Moderna COVID-19 Vaccine (2024-2025 Formula) may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances. The timing of the additional doses may be based on the individual’s clinical circumstances.

1: Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
2: COVID-19 vaccine, each dose of the three-doses series given one month apart, refers to Moderna COVID-19 vaccines. For individuals with certain kinds of immunocompromise turning from 11 years to 12 years of age during the vaccination series, complete the 3-dose series with 1 or 2 doses, as applicable, of SPIKEVAX (COVID-19 Vaccine, mRNA) (2024-2025 Formula) on or after the date the individual turns 12 years of age. If the individual turning 12 years of age receives two doses of SPIKEVAX (COVID-19 Vaccine, mRNA) (2024-2025 Formula) to complete the vaccination series or receives a dose of SPIKEVAX (COVID-19 Vaccine, mRNA) (2024-2025 Formula) less than 2 months after receipt of the last previous dose of COVID-19 vaccine to complete the vaccination series, then those uses of SPIKEVAX (COVID-19 Vaccine, mRNA) (2024-2025 Formula) are authorized under EUA. The FDA has authorized under EUA these uses of SPIKEVAX (COVID-19 Vaccine, mRNA) (2024-2025 Formula), which is an FDA-licensed vaccine indicated for active immunization to prevent COVID-19 in individuals 12 years of age and older. Refer to www.spikevax.com/pi for additional information about SPIKEVAX (COVID-19 Vaccine, mRNA) (2024-2025 Formula).
3: These prior COVID-19 vaccines are no longer authorized for use in the U.S.
4: For immunocompromised individuals 6 months through 4 years of age, the last dose of a COVID-19 vaccine (2024-2025 Formula) refers to a dose with Moderna COVID-19 Vaccine (2024-2025 Formula).
5: For immunocompromised individuals 5 years through 11 years of age, the last dose of a COVID-19 vaccine (2024-2025 Formula) refers to a dose with Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) or Moderna COVID-19 Vaccine (2024-2025 Formula).